DTRM Biopharma

DTRM Biopharma is a clinical-stage biopharmaceutical company focused on developing innovative small molecule therapies for oncology, with a primary emphasis on B-cell malignancies. The company's lead candidate, DTRMWXHS-12, is a potent, selective, and irreversible Bruton's tyrosine kinase (BTK) inhibitor designed to overcome resistance and improve efficacy in patients with chronic lymphocytic leukemia (CLL) and other lymphomas. DTRM Biopharma utilizes a combination therapy approach, exploring its proprietary compounds alongside other agents to enhance clinical outcomes. Headquartered in Hangzhou, China, with operations in the United States, the company is backed by prominent life science investors including Lilly Asia Ventures and Qiming Venture Partners.